Mineralys Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
/ 
Frequently asked questions
To buy Mineralys Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Mineralys Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Mineralys Therapeutics Inc. is MLYS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Mineralys Therapeutics Inc. has its primary listing on NASDAQ. You can trade Mineralys Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Mineralys Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Mineralys Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Mineralys Therapeutics Inc..